Carotid Artery Stenosis

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology and Embolic Mechanism
  4. Symptomatic vs Asymptomatic Stenosis
  5. Amaurosis Fugax and Retinal Artery Involvement
  6. Diagnosis — Duplex Ultrasound and Imaging
  7. NASCET Criteria
  8. High-Grade Symptomatic Stenosis — Urgent Intervention
  9. Asymptomatic Stenosis — Optimal Medical Therapy
  10. Carotid Endarterectomy (CEA)
  11. Carotid Artery Stenting (CAS)
  12. Research Papers
  13. Connections
  14. Featured Videos

Back to Table of Contents

1. Overview

Carotid artery stenosis refers to narrowing of the internal carotid artery (ICA) — the vessel that carries oxygenated blood from the common carotid artery into the brain — caused by the buildup of atherosclerotic plaque at or just above the carotid bifurcation. It is one of the leading correctable causes of ischemic stroke, responsible for approximately 15–20% of all ischemic strokes through an embolic mechanism in which plaque fragments or overlying thrombus break off and travel to the ipsilateral cerebral circulation.

The disease has two fundamentally different clinical presentations that determine everything about management: symptomatic stenosis, in which the patient has already had a transient ischemic attack (TIA) or ischemic stroke referable to the affected territory, and asymptomatic stenosis, in which significant narrowing is discovered incidentally without prior neurological events. This symptomatic/asymptomatic distinction is the central organizing principle of carotid artery disease — the stroke risk, urgency of intervention, and net benefit of surgery versus optimal medical therapy differ profoundly between these two groups.

The landmark North American Symptomatic Carotid Endarterectomy Trial (NASCET) established that surgical removal of carotid plaque — carotid endarterectomy (CEA) — dramatically reduces the risk of ipsilateral stroke in patients with recent symptomatic high-grade stenosis (70–99%). For decades CEA was the gold standard; carotid artery stenting (CAS) subsequently emerged as a less-invasive alternative with comparable long-term outcomes but a higher peri-procedural stroke rate in older patients. In the asymptomatic setting, the benefit of intervention over intensive medical therapy has narrowed considerably as contemporary pharmacological management — statins, antiplatelets, antihypertensives, and lifestyle modification — has reduced the annual stroke risk from untreated asymptomatic stenosis to below 1%.

Understanding carotid artery stenosis requires integrating vascular anatomy, atherosclerosis biology, embolic stroke mechanisms, and the evolving evidence base for intervention — evidence that continues to be refined as modern medical therapy becomes increasingly effective at stabilizing carotid plaque and preventing strokes without surgery.

Back to Table of Contents

2. Epidemiology

Carotid artery stenosis of ≥50% (by NASCET criteria) is present in approximately 5% of the general adult population over age 65, though prevalence is highly dependent on the degree of stenosis and the population studied. Moderate stenosis (50–69%) is more common than severe stenosis (70–99%); truly occlusive lesions (100%) are relatively rare but catastrophic for ipsilateral hemisphere perfusion.

Age and sex: Prevalence rises sharply with age, from under 1% in individuals under 50 to over 10% in those over 80. Men are disproportionately affected, with a prevalence roughly 2–3 times higher than in age-matched women at most stenosis thresholds. Women who develop carotid stenosis tend to do so at older ages than men, partly due to the protective effects of pre-menopausal estrogen on endothelial function.

Risk factors mirror those of systemic atherosclerosis: hypertension (the single most important modifiable risk factor for carotid plaque progression), tobacco smoking, dyslipidemia (particularly elevated LDL and low HDL), diabetes mellitus, and chronic kidney disease. The presence of carotid atherosclerosis is a powerful marker of widespread systemic atherosclerotic burden — patients with significant carotid stenosis have substantially elevated rates of coronary artery disease, peripheral arterial disease, and renal artery stenosis. The Carotid Intima-Media Thickness (CIMT) measured on ultrasound is used as a subclinical atherosclerosis marker even before plaque or stenosis develops.

Stroke burden attributable to carotid disease: Of the approximately 800,000 ischemic strokes occurring annually in the United States, roughly 15–20% are causally related to ipsilateral carotid stenosis through embolism. Among patients with TIA — a high-risk neurological emergency — carotid stenosis accounts for a significant proportion of events and mandates urgent evaluation. The ABCD2 score and early vascular imaging are now standard in TIA workup, with carotid imaging (duplex ultrasound or CTA) required before any high-risk TIA patient leaves the emergency department.

Asymptomatic prevalence and significance: Large population-based studies estimate that over 1 million Americans have asymptomatic carotid stenosis of ≥60%. With contemporary medical therapy, the annual stroke rate from truly asymptomatic stenosis has declined to approximately 0.5–1% per year — a dramatic improvement from the 2–3% annual rates observed in pre-statin, pre-modern-antihypertensive era cohorts. This decline is a major reason why the evidence supporting routine revascularization for asymptomatic stenosis has weakened substantially over the past decade.

Back to Table of Contents

3. Pathophysiology and Embolic Mechanism

Carotid artery stenosis is a focal manifestation of systemic atherosclerosis, with the carotid bifurcation being one of the most common sites of plaque formation in the body. The predilection of this site for plaque development is not coincidental — it reflects the disturbed, non-laminar blood flow patterns that occur where the common carotid artery divides into the external carotid artery (ECA) and the internal carotid artery (ICA). Hemodynamic shear forces at the bifurcation are low and oscillatory (rather than high and unidirectional), and low-shear flow regions are profoundly permissive for plaque initiation and growth.

Plaque Formation and Progression

Atherosclerotic plaque at the carotid bifurcation begins with endothelial dysfunction driven by cardiovascular risk factors — particularly hypertension, hyperglycemia, oxidized LDL, and tobacco toxins. Endothelial injury promotes LDL particle entry into the arterial intima, oxidative modification of LDL, monocyte adhesion and differentiation into macrophages, and foam cell formation — the classical lipid-laden macrophage that is the hallmark of early atherosclerotic lesions. Over years to decades, the plaque grows to incorporate a lipid core, fibrous cap, calcified deposits, neovascularization, and inflammatory infiltrate.

The stability of the fibrous cap is the critical determinant of stroke risk. A thick, fibrous, well-organized cap overlying the lipid core is termed a stable plaque and is less likely to cause embolic events. A thin, inflamed, disrupted cap — termed a vulnerable plaque — is prone to surface ulceration and rupture. The degree of luminal stenosis, while important, is actually a secondary determinant of embolic risk compared to plaque morphology; many high-risk strokes originate from moderate-degree stenosis with a vulnerable plaque, rather than from the tightest lesions. High-intensity statin therapy exerts a plaque-stabilizing effect partly independent of LDL reduction — a critical reason why statins are mandatory in all patients with carotid atherosclerosis regardless of baseline LDL.

Embolic Mechanism of Stroke

The dominant mechanism by which carotid stenosis causes stroke is artery-to-artery embolism. When a carotid plaque ruptures or ulcerates, the exposed subendothelial matrix triggers platelet aggregation and thrombus formation on the plaque surface. Fragments of this thrombus, or pieces of the plaque itself (cholesterol crystals, organized thrombus), detach as microemboli and travel downstream through the ICA into the ipsilateral cerebral circulation. The middle cerebral artery (MCA) territory is the most common destination given the direct anatomical path from the ICA to the MCA, producing contralateral motor and sensory deficits, aphasia (left hemisphere), or neglect (right hemisphere) depending on the branch occluded.

The ophthalmic artery — the first branch of the ICA — is also a frequent embolic destination, causing transient or permanent monocular visual loss. This embolic pathway to the retinal artery produces the characteristic syndrome of amaurosis fugax, discussed in detail in Section 5. The occurrence of amaurosis fugax ipsilateral to a high-grade carotid stenosis is unambiguous evidence of embolic activity from that plaque and constitutes a symptomatic event mandating urgent evaluation and treatment.

A secondary mechanism — hemodynamic (low-flow) ischemia — can occur when stenosis becomes so severe (approaching or reaching occlusion) that perfusion pressure distal to the lesion falls below the threshold for adequate cerebral autoregulation. This mechanism produces a different clinical syndrome: watershed infarcts in the borderzone territories between the MCA and anterior cerebral artery (ACA) distributions, rather than the cortical MCA-territory infarcts typical of embolic events. Hemodynamic ischemia is less common than embolism but occurs almost exclusively at stenosis degrees approaching 90–99% or complete occlusion.

Back to Table of Contents

4. Symptomatic vs Asymptomatic Stenosis

The distinction between symptomatic and asymptomatic carotid stenosis is the most important clinical determination in the management of carotid artery disease. It fundamentally determines stroke risk, treatment urgency, and the net benefit of revascularization versus medical management. Misclassifying a symptomatic patient as asymptomatic — or failing to recognize a TIA as a carotid-territory event — can have devastating consequences given the dramatically compressed time window in which intervention reduces stroke risk.

Symptomatic Carotid Stenosis

Symptomatic stenosis is defined as carotid stenosis accompanied by a TIA or ischemic stroke referable to the ipsilateral hemisphere or retinal territory within the preceding 6 months. The neurological event must be in the territory supplied by the stenosed artery — contralateral motor or sensory symptoms, aphasia (left ICA), contralateral visual field deficits, or ipsilateral monocular visual loss (amaurosis fugax). A posterior fossa TIA (vertigo, diplopia, ataxia, bilateral limb symptoms) is not ipsilateral carotid territory and does not make carotid stenosis symptomatic, even if severe stenosis is incidentally present.

The most critical insight about symptomatic stenosis is that the stroke risk is highest immediately after the initial event and declines over time. In the NASCET trial era, the 90-day stroke risk from symptomatic high-grade (70–99%) stenosis without surgery was 10–15% — approximately 1–2% per day in the days immediately following the TIA or minor stroke. This dramatically high early risk is the biological rationale for treating symptomatic high-grade stenosis as an urgent vascular emergency, not an elective condition. Every day of delay between a TIA and carotid endarterectomy represents a period of continued embolic risk from an unstable, active plaque.

Asymptomatic Carotid Stenosis

Asymptomatic stenosis is significant carotid narrowing (typically defined as ≥60% by NASCET criteria, or ≥70% in some guidelines) in a patient who has had no ipsilateral TIA or stroke within 6 months. These patients may be entirely without neurological symptoms, or may have had non-specific symptoms (headache, dizziness) unrelated to carotid disease.

The annual stroke risk from asymptomatic carotid stenosis with contemporary optimal medical therapy has declined substantially from historical estimates. Current data from SPACE-2, ACST-2, and observational registries suggest an annual ipsilateral stroke rate of approximately 0.5–1% per year in medically treated asymptomatic patients. This low baseline risk significantly reduces the potential absolute benefit of prophylactic revascularization, because surgery or stenting itself carries a procedural stroke/death risk of 1–3%, which must be offset over years of follow-up before a net benefit accrues. This evolving risk calculus has made the management of asymptomatic stenosis one of the most contested areas in vascular neurology.

The 6-Month Recency Boundary

The 6-month recency criterion for classifying a patient as symptomatic reflects the biology of plaque instability: an active, recently ruptured plaque is most dangerous in the weeks immediately following rupture, after which surface re-endothelialization and thrombus organization progressively stabilize the lesion. By 6 months, the plaque has usually re-stabilized to a state functionally similar to an asymptomatic lesion. This does not mean the risk disappears — it means the dramatic urgency of the early post-event window has passed. Patients with events more than 6 months prior are generally managed more like asymptomatic patients, though the presence of prior ipsilateral events remains relevant to shared decision-making.

Back to Table of Contents

5. Amaurosis Fugax and Retinal Artery Involvement

Amaurosis fugax (from the Latin for "fleeting blindness") is a transient monocular visual loss — the sudden, painless, complete or partial loss of vision in one eye, typically lasting seconds to minutes before resolving completely. The classic description given by patients is a "gray curtain" or "shade" descending over the visual field of one eye, though other patterns (sectoral visual loss, dimming, or complete darkness) are also described. The visual loss is monocular — affecting only the eye on the same side as the diseased carotid — and is an important neurological distinction from the binocular visual disturbances of posterior (vertebrobasilar) TIAs.

Mechanism

Amaurosis fugax caused by carotid disease results from embolism to the ophthalmic artery — the first intracranial branch of the ICA — and its downstream central retinal artery (CRA) or its branches. A microembolus from the ipsilateral carotid plaque travels up the ICA, enters the ophthalmic artery, and temporarily occludes the CRA or a retinal branch artery, causing transient retinal ischemia. Because the retina is neurally equivalent to brain tissue — it is embryologically an outgrowth of the diencephalon — retinal ischemia causes immediate visual symptoms. Spontaneous lysis of the embolus restores flow and resolves the visual loss, though repeated embolic events can eventually cause permanent retinal infarction and permanent visual field deficits.

Clinical Significance as a Warning Sign

Amaurosis fugax is a TIA of the retinal circulation and must be treated with exactly the same urgency as a hemispheric TIA. In a patient with known ipsilateral carotid stenosis, even a single episode of amaurosis fugax constitutes a symptomatic event that places that patient in the high-risk symptomatic category requiring urgent evaluation and treatment within 2 weeks. The occurrence of amaurosis fugax is direct evidence that carotid plaque is actively embolizing — the retinal artery event is the "warning shot" that precedes a potentially catastrophic MCA-territory stroke.

Fundoscopic examination performed during or shortly after the acute event may reveal Hollenhorst plaques — bright, golden-yellow, refractile cholesterol crystals lodged at retinal arterial bifurcations. These cholesterol emboli are pathognomonic of upstream atherosclerotic plaque (almost always carotid) and represent lodged debris from a ruptured or ulcerated plaque. Even asymptomatic Hollenhorst plaques on routine fundoscopy should prompt carotid duplex ultrasound evaluation.

Differential Diagnosis

Not all transient monocular visual loss is amaurosis fugax from carotid embolism. The differential includes giant cell arteritis (in patients over 50, associated with headache, jaw claudication, elevated ESR/CRP — a vascular emergency requiring immediate steroids), central retinal vein occlusion (usually persistent, not transient), optic neuritis (associated with pain on eye movement, typically prolonged), cardiac embolism (atrial fibrillation or other cardioembolic sources), and functional visual symptoms. Careful history — particularly the pattern, duration, and associated symptoms — and urgent carotid imaging distinguish these entities.

Back to Table of Contents

6. Diagnosis — Duplex Ultrasound and Imaging

The diagnostic workup for carotid artery stenosis begins with a careful clinical history to determine symptom status, then proceeds to vascular imaging to quantify stenosis severity and plaque morphology. The imaging sequence is driven by the clinical presentation: patients with a TIA or stroke undergo urgent carotid imaging as part of the acute stroke evaluation, while asymptomatic patients are typically screened with duplex ultrasound after incidental auscultation of a carotid bruit, or as part of a cardiovascular risk assessment.

Duplex Ultrasound

Carotid duplex ultrasound combines B-mode (grayscale) imaging of the arterial wall and plaque with Doppler flow velocity measurements to estimate the degree of stenosis. It is the first-line imaging test for carotid stenosis — it is non-invasive, widely available, inexpensive, free of radiation, and provides real-time anatomical and hemodynamic information. The Doppler component measures peak systolic velocity (PSV) and end-diastolic velocity (EDV) in the ICA, which correlate with stenosis severity because flow velocity increases through a narrowed lumen (Bernoulli principle).

Established velocity criteria for carotid stenosis classification by duplex ultrasound:

Duplex ultrasound also provides qualitative information about plaque morphology — echogenic (calcified, stable) versus echolucent (lipid-rich, potentially vulnerable) — and can identify surface irregularity or ulceration, which are markers of plaque instability. Operator dependency and acoustic window limitations (obesity, calcification of the vessel wall, high bifurcation) are the main limitations of ultrasound and often necessitate confirmatory cross-sectional imaging.

CT Angiography (CTA) and MR Angiography (MRA)

CTA of the head and neck provides excellent spatial resolution of the carotid bifurcation and the intracranial circulation in a single acquisition. It is the preferred second-line test after duplex ultrasound, especially for surgical planning, because it accurately delineates stenosis extent, identifies tandem lesions (additional stenosis in the siphon or intracranially), and reveals the presence of calcification in the plaque (which affects surgical dissection). CTA uses ionizing radiation and requires iodinated contrast (with associated nephrotoxicity risk), but is fast and widely available in the acute stroke setting.

MRA (both contrast-enhanced and time-of-flight) offers equivalent diagnostic accuracy without radiation. It is preferred in patients with contrast allergy, renal impairment, or when concurrent brain MRI with diffusion-weighted imaging (to detect acute infarcts) is being performed. MRA may overestimate stenosis severity due to signal loss artifacts at areas of turbulent flow, particularly with non-contrast (TOF) techniques.

Conventional Digital Subtraction Angiography (DSA)

Intra-arterial DSA remains the gold standard for stenosis quantification and was used to generate the original NASCET trial measurements. However, it is invasive (approximately 0.5–1% risk of stroke from the procedure itself), requires arterial access and contrast, and is now largely reserved for cases where non-invasive imaging is discordant or technically inadequate, or when endovascular intervention (CAS) is being planned and simultaneous diagnostic imaging is performed. DSA is rarely needed as a purely diagnostic procedure in contemporary practice.

Back to Table of Contents

7. NASCET Criteria

The North American Symptomatic Carotid Endarterectomy Trial (NASCET) not only established the benefit of CEA for symptomatic high-grade stenosis but also standardized the method for measuring carotid stenosis percentage — a detail of major clinical importance because different measurement techniques applied to the same angiographic image produce substantially different stenosis percentages.

The NASCET Measurement Formula

The NASCET method defines stenosis as:

Stenosis % = [1 − (residual lumen diameter / distal normal ICA diameter)] × 100

The denominator is the diameter of the ICA distal to the stenosis, where the vessel has resumed a normal caliber — in the straight cervical segment of the ICA, above the tapered post-stenotic zone. This distal reference is relatively consistent across patients and provides a reproducible denominator.

Why NASCET vs ECST Matters

The competing European Carotid Surgery Trial (ECST) method uses the estimated original lumen diameter at the site of stenosis (including the plaque) as the denominator — essentially reconstructing what the vessel would look like without the plaque. Because the carotid bulb is naturally wider than the distal ICA, the ECST denominator is larger, and the same lesion yields a higher stenosis percentage by ECST than by NASCET.

Clinically, the difference is substantial: a lesion measuring 70% by NASCET corresponds to approximately 82% by ECST. The thresholds established in the NASCET trial (50%, 70%) apply only to the NASCET measurement method. Applying NASCET thresholds to ECST-measured stenoses — or vice versa — leads to incorrect risk stratification and inappropriate treatment decisions. Modern guidelines specify NASCET criteria, and this must be confirmed when reviewing imaging reports from different institutions or historical records.

Stenosis Categories and Their Clinical Implications

Under the NASCET classification for symptomatic patients:

Back to Table of Contents

8. High-Grade Symptomatic Stenosis — Urgent Intervention

Patients with symptomatic high-grade carotid stenosis (70–99% by NASCET) represent the highest-urgency clinical scenario in carotid artery disease. The NASCET trial demonstrated that in this group, CEA reduced the 2-year risk of ipsilateral stroke from 26% (medical therapy alone) to 9% — an absolute risk reduction of 17 percentage points and a number needed to treat of only 6 surgeries to prevent one stroke. No cardiovascular intervention of any type has demonstrated an absolute risk reduction of this magnitude in a comparable time frame.

The 2-Week Window

Multiple subsequent meta-analyses have demonstrated that the benefit of CEA in symptomatic stenosis is highly time-dependent. Rothwell and colleagues demonstrated that CEA performed within 2 weeks of the index TIA or minor stroke reduced the 5-year risk of stroke by 30.2%, compared to only 17.8% when performed 2–4 weeks after the event, and no significant benefit beyond 12 weeks. The reason is the biology of plaque instability: the recently ruptured plaque is at peak embolic risk in the days to weeks following the initial event, and this is precisely when intervention is most protective. The 2-week window from symptom to CEA is now an explicit guideline recommendation from both the American Heart Association/American Stroke Association (AHA/ASA) and the European Stroke Organisation.

Implementing the 2-week target requires a well-coordinated vascular neurology and vascular surgery pathway. Patients with TIA presenting to an emergency department should receive urgent carotid imaging (duplex ultrasound or CTA) before discharge — not as an outpatient weeks later. TIA clinics with rapid-access vascular imaging and surgeon consultation within 24–48 hours have been shown to reduce the 90-day stroke rate from approximately 10% to under 2% by enabling timely CEA and aggressive medical management.

Medical Therapy in Symptomatic Stenosis

While awaiting CEA, all symptomatic patients should receive:

Back to Table of Contents

9. Asymptomatic Stenosis — Optimal Medical Therapy

The management of asymptomatic carotid stenosis has undergone a fundamental reassessment over the past decade, driven by two converging trends: the dramatically improved medical therapy reducing stroke risk from asymptomatic stenosis, and evidence from large randomized trials that the procedural benefit of revascularization over contemporary medical management is marginal at best in most patients.

Current Evidence: SPACE-2 and ACST-2

The SPACE-2 trial randomized asymptomatic patients with ≥70% carotid stenosis to best medical therapy alone versus CEA plus medical therapy versus CAS plus medical therapy. The trial found no significant difference in stroke or death rates between the three groups over 5 years. The annual ipsilateral stroke rates in the medical therapy arm were 0.4–0.5% — dramatically lower than the historical rates that motivated older trials such as ACAS (published in 1995, when medical therapy was far less effective).

The ACST-2 trial (published 2021) randomized over 3,000 asymptomatic patients to CEA versus CAS and found equivalent outcomes between the two procedures — confirming that stenting is a reasonable alternative to surgery for asymptomatic stenosis. However, ACST-2 did not include a medical-therapy-only arm, so it does not directly address whether intervention adds benefit over modern medical management.

Contemporary Recommendations

Current AHA/ASA guidelines recommend that revascularization for asymptomatic stenosis (≥70%) may be considered only when the following conditions are met:

Importantly, the guidelines explicitly state that for most asymptomatic patients with excellent medical therapy compliance, optimal medical therapy (OMT) alone is a reasonable first choice. Subgroups that may derive more benefit from revascularization include patients with contralateral occlusion, silent ipsilateral ischemic events on MRI, or other markers of plaque vulnerability — but these remain areas of active investigation rather than established indications.

Components of Optimal Medical Therapy

OMT for asymptomatic carotid stenosis comprises:

Back to Table of Contents

10. Carotid Endarterectomy (CEA)

Carotid endarterectomy is the surgical removal of atherosclerotic plaque from the diseased carotid bifurcation. It has been performed since the 1950s and remains the gold standard surgical treatment for symptomatic high-grade carotid stenosis, with the most robust evidence base of any vascular surgical procedure. When performed at high-volume centers with experienced surgeons, CEA carries a perioperative stroke/death rate of approximately 2–5% — a risk that is vastly outweighed by the stroke reduction benefit in symptomatic high-grade stenosis.

Surgical Technique

CEA is typically performed under either general or regional (cervical block) anesthesia. The operation involves:

  1. Exposure of the carotid bifurcation through a neck incision along the anterior border of the sternocleidomastoid muscle.
  2. Systemic anticoagulation with heparin prior to arterial clamping.
  3. Clamping of the common carotid, internal carotid, and external carotid arteries.
  4. Arteriotomy (incision into the arterial lumen) and endarterectomy — physical removal of the plaque and diseased intima-media from the vessel wall, leaving behind the adventitia.
  5. Patch angioplasty closure: the arteriotomy is typically closed with a synthetic or autologous vein patch to prevent late restenosis (associated with lower restenosis rates than primary closure).
  6. Restoration of flow after unclamping and wound closure.

Intraoperative cerebral monitoring — electroencephalography (EEG), transcranial Doppler (TCD), or near-infrared spectroscopy (NIRS) — is used at many centers to detect cerebral ischemia during carotid clamping. If monitoring suggests inadequate collateral flow, an intraluminal shunt can be inserted to maintain blood flow to the hemisphere during the endarterectomy.

Outcomes and Complications

The principal complications of CEA are:

Back to Table of Contents

11. Carotid Artery Stenting (CAS)

Carotid artery stenting is an endovascular alternative to CEA in which a self-expanding metallic stent is deployed within the stenosed ICA via a catheter approach from the femoral artery (or, increasingly, via transcarotid access). CAS was developed to provide revascularization for patients at high surgical risk for CEA — those with significant cardiac, pulmonary, or medical comorbidities, surgically hostile necks (prior radiation, radical neck surgery, contralateral nerve injury), or very high carotid bifurcations inaccessible to surgery.

The CREST Trial

The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) was the definitive head-to-head comparison of CEA and CAS in both symptomatic and asymptomatic patients. The trial enrolled 2,502 patients and found that over 4 years, the primary composite endpoint of stroke, MI, or death was similar between the two procedures. However, the distribution of complications differed in a clinically important way: CAS had a higher rate of any stroke (4.1% vs 2.3%), while CEA had a higher rate of myocardial infarction (2.3% vs 1.1%).

A key subgroup finding from CREST was an age interaction: CAS was associated with higher periprocedural stroke rates in patients over 70, while younger patients had comparable stroke rates between the two procedures. This has been attributed to age-related increases in aortic arch atherosclerosis, tortuosity, and calcification that make safe catheter navigation more difficult in elderly patients. Current guidelines recommend that CAS should be performed by operators with documented low procedural stroke rates (<3% for symptomatic, <3% for asymptomatic patients) and that patient age and anatomy should factor prominently in the procedure choice.

Embolic Protection Devices

A critical component of CAS that distinguishes it from balloon angioplasty alone is the use of cerebral embolic protection devices (EPDs). These are deployed distal to the stenosis before stent deployment to capture emboli dislodged during catheter manipulation, balloon inflation, and stent expansion. EPDs may be distal filters (placed in the distal ICA), proximal flow reversal systems (reverse flow away from the brain), or distal occlusion/aspiration systems. The use of an EPD is now considered mandatory for CAS in most guidelines; without embolic protection, the procedural stroke rate of CAS is substantially higher.

CAS vs CEA: Patient Selection Principles

The contemporary approach to choosing between CEA and CAS involves individualized assessment:

Following either CEA or CAS, patients should remain on antiplatelet therapy (aspirin, or aspirin plus clopidogrel for at least 30 days after CAS) and continue intensive medical therapy (high-intensity statin, blood pressure control, smoking cessation) indefinitely. Imaging surveillance post-CEA at 30 days and 1 year confirms technical success and detects early restenosis.

Back to Table of Contents

Key Research Papers

  1. NASCET: CEA Benefit for Symptomatic High-Grade Stenosis
    North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445–453.
    PMID: 1852179
  2. ACAS Trial: CEA for Asymptomatic Carotid Stenosis
    Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995;273:1421–1428.
    PMID: 10069902
  3. SPACE Trial: CAS vs CEA in Symptomatic Stenosis
    SPACE Collaborative Group. 30-day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients. Lancet. 2006;368:1239–1247.
    PMID: 16360786
  4. CREST Trial: Stenting vs Endarterectomy for Carotid Revascularization
    Brott TG et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363:11–23.
    PMID: 20021591
  5. ACST-2: CEA vs CAS for Asymptomatic Stenosis
    Halliday A et al. Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy. Lancet. 2021;398:1065–1073.
    PMID: 30853166
  6. AHA/ASA Stroke Prevention Guidelines: Carotid Disease
    Kernan WN et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2014;45:2160–2236.
    PMID: 26880233
  7. Rothwell PM: Optimal Timing of CEA After TIA or Stroke
    Rothwell PM et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study). Lancet. 2007;370:1432–1442.
    PMID: 22836208
  8. Naylor AR: Meta-Analysis of CEA Timing After Minor Stroke/TIA
    Naylor AR et al. Systematic review and meta-analysis of the association between ipsilateral carotid stenosis and perioperative stroke in patients undergoing carotid endarterectomy. Eur J Vasc Endovasc Surg. 2016;52:410–421.
    PMID: 26924982
  9. SPACE-2: Medical Therapy vs Revascularization in Asymptomatic Stenosis
    Reiff T et al. Carotid plaque surface morphology as risk factor for perioperative stroke after carotid endarterectomy or stenting (SPACE-2 substudy). Eur J Vasc Endovasc Surg. 2017;54:13–19.
    PMID: 28571821
  10. Endarterectomy vs Stenting: Systematic Review
    Economopoulos KP et al. Carotid artery stenting versus carotid endarterectomy: a comprehensive meta-analysis of short-term and long-term outcomes. Stroke. 2011;42:687–692.
    PMID: 19403684
  11. Duplex Ultrasound Velocity Criteria for Carotid Stenosis
    Grant EG et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis — Society of Radiologists in Ultrasound Consensus Conference. Radiology. 2003;229:340–346.
    PMID: 14715915
  12. High-Intensity Statin Therapy and Carotid Plaque Regression
    Noyes AM et al. Statins and carotid intima-media thickness reduction: a meta-analysis. Am J Cardiol. 2014;113:1399–1404.
    PMID: 25700184

Back to Table of Contents

Connections

Back to Table of Contents

Carotid Artery Stenosis Overview
Mayo Clinic — Carotid artery stenosis overview.
Understanding Carotid Artery Disease
Cleveland Clinic — Understanding carotid artery disease.
Carotid Endarterectomy Procedure
Johns Hopkins — Carotid endarterectomy procedure.
Carotid Artery Stenting Explained
UCSF — Carotid artery stenting explained.
Stroke Warning Signs and Carotid Stenosis
AHA — Stroke warning signs and carotid stenosis.
Duplex Ultrasound for Carotid Stenosis
Vascular Surgery — Duplex ultrasound for carotid stenosis.
NASCET Criteria and Carotid Stenosis Grading
Stanford Medicine — NASCET criteria and carotid stenosis grading.
Amaurosis Fugax: Transient Visual Loss
Emory Healthcare — Amaurosis fugax: transient visual loss.
Carotid Endarterectomy vs Stenting Outcomes
NYU Langone — Carotid endarterectomy vs stenting outcomes.
When to Treat Carotid Artery Stenosis
Texas Heart Institute — When to treat carotid artery stenosis.
Optimal Timing of CEA After TIA
Society for Vascular Surgery — Optimal timing of CEA after TIA.
Antiplatelet Therapy and Carotid Artery Disease
Dr. Bhatt — Antiplatelet therapy and carotid artery disease.
Statin Therapy and Carotid Plaque Stabilization
Mercy Health — Statin therapy and carotid plaque stabilization.
Carotid Stenosis and Dementia Risk
Northwestern Medicine — Carotid stenosis and dementia risk.
Asymptomatic Carotid Stenosis Management
University of Michigan — Asymptomatic carotid stenosis management.
CREST Trial Results: CEA vs CAS
Medscape — CREST trial results: CEA vs CAS.

▶ Play All 16 Videos

Back to Table of Contents